The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Hereditary Amyloidosis Treatment Market Research Report 2025
Synopsis
Hereditary Amyloidosis is one of the amyloidosis disease that is caused by inherited genetic mutation.
The global Hereditary Amyloidosis Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Hereditary Amyloidosis Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hereditary Amyloidosis Treatment.
Report Scope
The Hereditary Amyloidosis Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hereditary Amyloidosis Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hereditary Amyloidosis Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Baxter
Johnson & Johnson
Alnylam Pharmaceuticals
Pfizer
Prothena
GlaxoSmithKline
Ionis Pharmaceuticals
BridgeBio Pharma
SOM Innovation Biotech
Segment by Type
Drug Treatment
Surgical Treatment
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hereditary Amyloidosis Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Hereditary Amyloidosis is one of the amyloidosis disease that is caused by inherited genetic mutation.
The global Hereditary Amyloidosis Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Hereditary Amyloidosis Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hereditary Amyloidosis Treatment.
Report Scope
The Hereditary Amyloidosis Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hereditary Amyloidosis Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hereditary Amyloidosis Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Baxter
Johnson & Johnson
Alnylam Pharmaceuticals
Pfizer
Prothena
GlaxoSmithKline
Ionis Pharmaceuticals
BridgeBio Pharma
SOM Innovation Biotech
Segment by Type
Drug Treatment
Surgical Treatment
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hereditary Amyloidosis Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hereditary Amyloidosis Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Drug Treatment
1.2.3 Surgical Treatment
1.3 Market by Application
1.3.1 Global Hereditary Amyloidosis Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hereditary Amyloidosis Treatment Market Perspective (2019-2030)
2.2 Hereditary Amyloidosis Treatment Growth Trends by Region
2.2.1 Global Hereditary Amyloidosis Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Hereditary Amyloidosis Treatment Historic Market Size by Region (2019-2024)
2.2.3 Hereditary Amyloidosis Treatment Forecasted Market Size by Region (2025-2030)
2.3 Hereditary Amyloidosis Treatment Market Dynamics
2.3.1 Hereditary Amyloidosis Treatment Industry Trends
2.3.2 Hereditary Amyloidosis Treatment Market Drivers
2.3.3 Hereditary Amyloidosis Treatment Market Challenges
2.3.4 Hereditary Amyloidosis Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hereditary Amyloidosis Treatment Players by Revenue
3.1.1 Global Top Hereditary Amyloidosis Treatment Players by Revenue (2019-2024)
3.1.2 Global Hereditary Amyloidosis Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Hereditary Amyloidosis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Hereditary Amyloidosis Treatment Revenue
3.4 Global Hereditary Amyloidosis Treatment Market Concentration Ratio
3.4.1 Global Hereditary Amyloidosis Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hereditary Amyloidosis Treatment Revenue in 2023
3.5 Hereditary Amyloidosis Treatment Key Players Head office and Area Served
3.6 Key Players Hereditary Amyloidosis Treatment Product Solution and Service
3.7 Date of Enter into Hereditary Amyloidosis Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hereditary Amyloidosis Treatment Breakdown Data by Type
4.1 Global Hereditary Amyloidosis Treatment Historic Market Size by Type (2019-2024)
4.2 Global Hereditary Amyloidosis Treatment Forecasted Market Size by Type (2025-2030)
5 Hereditary Amyloidosis Treatment Breakdown Data by Application
5.1 Global Hereditary Amyloidosis Treatment Historic Market Size by Application (2019-2024)
5.2 Global Hereditary Amyloidosis Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Hereditary Amyloidosis Treatment Market Size (2019-2030)
6.2 North America Hereditary Amyloidosis Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Hereditary Amyloidosis Treatment Market Size by Country (2019-2024)
6.4 North America Hereditary Amyloidosis Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Hereditary Amyloidosis Treatment Market Size (2019-2030)
7.2 Europe Hereditary Amyloidosis Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Hereditary Amyloidosis Treatment Market Size by Country (2019-2024)
7.4 Europe Hereditary Amyloidosis Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Hereditary Amyloidosis Treatment Market Size (2019-2030)
8.2 Asia-Pacific Hereditary Amyloidosis Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Hereditary Amyloidosis Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Hereditary Amyloidosis Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Hereditary Amyloidosis Treatment Market Size (2019-2030)
9.2 Latin America Hereditary Amyloidosis Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Hereditary Amyloidosis Treatment Market Size by Country (2019-2024)
9.4 Latin America Hereditary Amyloidosis Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hereditary Amyloidosis Treatment Market Size (2019-2030)
10.2 Middle East & Africa Hereditary Amyloidosis Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Hereditary Amyloidosis Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Hereditary Amyloidosis Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Baxter
11.1.1 Baxter Company Detail
11.1.2 Baxter Business Overview
11.1.3 Baxter Hereditary Amyloidosis Treatment Introduction
11.1.4 Baxter Revenue in Hereditary Amyloidosis Treatment Business (2019-2024)
11.1.5 Baxter Recent Development
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Detail
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson Hereditary Amyloidosis Treatment Introduction
11.2.4 Johnson & Johnson Revenue in Hereditary Amyloidosis Treatment Business (2019-2024)
11.2.5 Johnson & Johnson Recent Development
11.3 Alnylam Pharmaceuticals
11.3.1 Alnylam Pharmaceuticals Company Detail
11.3.2 Alnylam Pharmaceuticals Business Overview
11.3.3 Alnylam Pharmaceuticals Hereditary Amyloidosis Treatment Introduction
11.3.4 Alnylam Pharmaceuticals Revenue in Hereditary Amyloidosis Treatment Business (2019-2024)
11.3.5 Alnylam Pharmaceuticals Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Detail
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Hereditary Amyloidosis Treatment Introduction
11.4.4 Pfizer Revenue in Hereditary Amyloidosis Treatment Business (2019-2024)
11.4.5 Pfizer Recent Development
11.5 Prothena
11.5.1 Prothena Company Detail
11.5.2 Prothena Business Overview
11.5.3 Prothena Hereditary Amyloidosis Treatment Introduction
11.5.4 Prothena Revenue in Hereditary Amyloidosis Treatment Business (2019-2024)
11.5.5 Prothena Recent Development
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Company Detail
11.6.2 GlaxoSmithKline Business Overview
11.6.3 GlaxoSmithKline Hereditary Amyloidosis Treatment Introduction
11.6.4 GlaxoSmithKline Revenue in Hereditary Amyloidosis Treatment Business (2019-2024)
11.6.5 GlaxoSmithKline Recent Development
11.7 Ionis Pharmaceuticals
11.7.1 Ionis Pharmaceuticals Company Detail
11.7.2 Ionis Pharmaceuticals Business Overview
11.7.3 Ionis Pharmaceuticals Hereditary Amyloidosis Treatment Introduction
11.7.4 Ionis Pharmaceuticals Revenue in Hereditary Amyloidosis Treatment Business (2019-2024)
11.7.5 Ionis Pharmaceuticals Recent Development
11.8 BridgeBio Pharma
11.8.1 BridgeBio Pharma Company Detail
11.8.2 BridgeBio Pharma Business Overview
11.8.3 BridgeBio Pharma Hereditary Amyloidosis Treatment Introduction
11.8.4 BridgeBio Pharma Revenue in Hereditary Amyloidosis Treatment Business (2019-2024)
11.8.5 BridgeBio Pharma Recent Development
11.9 SOM Innovation Biotech
11.9.1 SOM Innovation Biotech Company Detail
11.9.2 SOM Innovation Biotech Business Overview
11.9.3 SOM Innovation Biotech Hereditary Amyloidosis Treatment Introduction
11.9.4 SOM Innovation Biotech Revenue in Hereditary Amyloidosis Treatment Business (2019-2024)
11.9.5 SOM Innovation Biotech Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Hereditary Amyloidosis Treatment Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Drug Treatment
Table 3. Key Players of Surgical Treatment
Table 4. Global Hereditary Amyloidosis Treatment Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Hereditary Amyloidosis Treatment Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Hereditary Amyloidosis Treatment Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Hereditary Amyloidosis Treatment Market Share by Region (2019-2024)
Table 8. Global Hereditary Amyloidosis Treatment Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Hereditary Amyloidosis Treatment Market Share by Region (2025-2030)
Table 10. Hereditary Amyloidosis Treatment Market Trends
Table 11. Hereditary Amyloidosis Treatment Market Drivers
Table 12. Hereditary Amyloidosis Treatment Market Challenges
Table 13. Hereditary Amyloidosis Treatment Market Restraints
Table 14. Global Hereditary Amyloidosis Treatment Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Hereditary Amyloidosis Treatment Market Share by Players (2019-2024)
Table 16. Global Top Hereditary Amyloidosis Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hereditary Amyloidosis Treatment as of 2023)
Table 17. Ranking of Global Top Hereditary Amyloidosis Treatment Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Hereditary Amyloidosis Treatment Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Hereditary Amyloidosis Treatment Product Solution and Service
Table 21. Date of Enter into Hereditary Amyloidosis Treatment Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Hereditary Amyloidosis Treatment Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Hereditary Amyloidosis Treatment Revenue Market Share by Type (2019-2024)
Table 25. Global Hereditary Amyloidosis Treatment Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Hereditary Amyloidosis Treatment Revenue Market Share by Type (2025-2030)
Table 27. Global Hereditary Amyloidosis Treatment Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Hereditary Amyloidosis Treatment Revenue Market Share by Application (2019-2024)
Table 29. Global Hereditary Amyloidosis Treatment Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Hereditary Amyloidosis Treatment Revenue Market Share by Application (2025-2030)
Table 31. North America Hereditary Amyloidosis Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Hereditary Amyloidosis Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Hereditary Amyloidosis Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Hereditary Amyloidosis Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Hereditary Amyloidosis Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Hereditary Amyloidosis Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Hereditary Amyloidosis Treatment Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Hereditary Amyloidosis Treatment Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Hereditary Amyloidosis Treatment Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Hereditary Amyloidosis Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Hereditary Amyloidosis Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Hereditary Amyloidosis Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Hereditary Amyloidosis Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Hereditary Amyloidosis Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Hereditary Amyloidosis Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 46. Baxter Company Detail
Table 47. Baxter Business Overview
Table 48. Baxter Hereditary Amyloidosis Treatment Product
Table 49. Baxter Revenue in Hereditary Amyloidosis Treatment Business (2019-2024) & (US$ Million)
Table 50. Baxter Recent Development
Table 51. Johnson & Johnson Company Detail
Table 52. Johnson & Johnson Business Overview
Table 53. Johnson & Johnson Hereditary Amyloidosis Treatment Product
Table 54. Johnson & Johnson Revenue in Hereditary Amyloidosis Treatment Business (2019-2024) & (US$ Million)
Table 55. Johnson & Johnson Recent Development
Table 56. Alnylam Pharmaceuticals Company Detail
Table 57. Alnylam Pharmaceuticals Business Overview
Table 58. Alnylam Pharmaceuticals Hereditary Amyloidosis Treatment Product
Table 59. Alnylam Pharmaceuticals Revenue in Hereditary Amyloidosis Treatment Business (2019-2024) & (US$ Million)
Table 60. Alnylam Pharmaceuticals Recent Development
Table 61. Pfizer Company Detail
Table 62. Pfizer Business Overview
Table 63. Pfizer Hereditary Amyloidosis Treatment Product
Table 64. Pfizer Revenue in Hereditary Amyloidosis Treatment Business (2019-2024) & (US$ Million)
Table 65. Pfizer Recent Development
Table 66. Prothena Company Detail
Table 67. Prothena Business Overview
Table 68. Prothena Hereditary Amyloidosis Treatment Product
Table 69. Prothena Revenue in Hereditary Amyloidosis Treatment Business (2019-2024) & (US$ Million)
Table 70. Prothena Recent Development
Table 71. GlaxoSmithKline Company Detail
Table 72. GlaxoSmithKline Business Overview
Table 73. GlaxoSmithKline Hereditary Amyloidosis Treatment Product
Table 74. GlaxoSmithKline Revenue in Hereditary Amyloidosis Treatment Business (2019-2024) & (US$ Million)
Table 75. GlaxoSmithKline Recent Development
Table 76. Ionis Pharmaceuticals Company Detail
Table 77. Ionis Pharmaceuticals Business Overview
Table 78. Ionis Pharmaceuticals Hereditary Amyloidosis Treatment Product
Table 79. Ionis Pharmaceuticals Revenue in Hereditary Amyloidosis Treatment Business (2019-2024) & (US$ Million)
Table 80. Ionis Pharmaceuticals Recent Development
Table 81. BridgeBio Pharma Company Detail
Table 82. BridgeBio Pharma Business Overview
Table 83. BridgeBio Pharma Hereditary Amyloidosis Treatment Product
Table 84. BridgeBio Pharma Revenue in Hereditary Amyloidosis Treatment Business (2019-2024) & (US$ Million)
Table 85. BridgeBio Pharma Recent Development
Table 86. SOM Innovation Biotech Company Detail
Table 87. SOM Innovation Biotech Business Overview
Table 88. SOM Innovation Biotech Hereditary Amyloidosis Treatment Product
Table 89. SOM Innovation Biotech Revenue in Hereditary Amyloidosis Treatment Business (2019-2024) & (US$ Million)
Table 90. SOM Innovation Biotech Recent Development
Table 91. Research Programs/Design for This Report
Table 92. Key Data Information from Secondary Sources
Table 93. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Hereditary Amyloidosis Treatment Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Hereditary Amyloidosis Treatment Market Share by Type: 2023 VS 2030
Figure 3. Drug Treatment Features
Figure 4. Surgical Treatment Features
Figure 5. Global Hereditary Amyloidosis Treatment Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global Hereditary Amyloidosis Treatment Market Share by Application: 2023 VS 2030
Figure 7. Hospitals Case Studies
Figure 8. Clinics Case Studies
Figure 9. Others Case Studies
Figure 10. Hereditary Amyloidosis Treatment Report Years Considered
Figure 11. Global Hereditary Amyloidosis Treatment Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 12. Global Hereditary Amyloidosis Treatment Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Hereditary Amyloidosis Treatment Market Share by Region: 2023 VS 2030
Figure 14. Global Hereditary Amyloidosis Treatment Market Share by Players in 2023
Figure 15. Global Top Hereditary Amyloidosis Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hereditary Amyloidosis Treatment as of 2023)
Figure 16. The Top 10 and 5 Players Market Share by Hereditary Amyloidosis Treatment Revenue in 2023
Figure 17. North America Hereditary Amyloidosis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 18. North America Hereditary Amyloidosis Treatment Market Share by Country (2019-2030)
Figure 19. United States Hereditary Amyloidosis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Canada Hereditary Amyloidosis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe Hereditary Amyloidosis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Hereditary Amyloidosis Treatment Market Share by Country (2019-2030)
Figure 23. Germany Hereditary Amyloidosis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. France Hereditary Amyloidosis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. U.K. Hereditary Amyloidosis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Italy Hereditary Amyloidosis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Russia Hereditary Amyloidosis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Nordic Countries Hereditary Amyloidosis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Hereditary Amyloidosis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Hereditary Amyloidosis Treatment Market Share by Region (2019-2030)
Figure 31. China Hereditary Amyloidosis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Japan Hereditary Amyloidosis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. South Korea Hereditary Amyloidosis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Southeast Asia Hereditary Amyloidosis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. India Hereditary Amyloidosis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Australia Hereditary Amyloidosis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America Hereditary Amyloidosis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Hereditary Amyloidosis Treatment Market Share by Country (2019-2030)
Figure 39. Mexico Hereditary Amyloidosis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Brazil Hereditary Amyloidosis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa Hereditary Amyloidosis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Hereditary Amyloidosis Treatment Market Share by Country (2019-2030)
Figure 43. Turkey Hereditary Amyloidosis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Saudi Arabia Hereditary Amyloidosis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Baxter Revenue Growth Rate in Hereditary Amyloidosis Treatment Business (2019-2024)
Figure 46. Johnson & Johnson Revenue Growth Rate in Hereditary Amyloidosis Treatment Business (2019-2024)
Figure 47. Alnylam Pharmaceuticals Revenue Growth Rate in Hereditary Amyloidosis Treatment Business (2019-2024)
Figure 48. Pfizer Revenue Growth Rate in Hereditary Amyloidosis Treatment Business (2019-2024)
Figure 49. Prothena Revenue Growth Rate in Hereditary Amyloidosis Treatment Business (2019-2024)
Figure 50. GlaxoSmithKline Revenue Growth Rate in Hereditary Amyloidosis Treatment Business (2019-2024)
Figure 51. Ionis Pharmaceuticals Revenue Growth Rate in Hereditary Amyloidosis Treatment Business (2019-2024)
Figure 52. BridgeBio Pharma Revenue Growth Rate in Hereditary Amyloidosis Treatment Business (2019-2024)
Figure 53. SOM Innovation Biotech Revenue Growth Rate in Hereditary Amyloidosis Treatment Business (2019-2024)
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
